查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1729649

日本胰岛素药物传输设备市场报告（按类型（药物、设备）和地区）2025-2033

Japan Insulin Drugs Delivery Devices Market Report by Type (Drug, Device), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024 年，日本胰岛素药物传输设备市场规模达 20 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 39 亿美元，2025-2033 年期间的成长率 (CAGR) 为 6.75%。日本糖尿病发生率的不断上升，加上新的胰岛素製剂和需要专门输送装置的药物的开发，是推动市场发展的主要因素。

胰岛素药物输送装置对于糖尿病患者来说是必不可少的工具，糖尿病是一种以胰岛素产生或利用受损为特征的慢性疾病。这些设备可以精确、方便地註射胰岛素，胰岛素是一种对调节血糖水平至关重要的荷尔蒙。胰岛素传递领域最显着的进步之一是胰岛素笔，它类似于普通笔，只需按一下按钮即可实现精确剂量。其精巧的设计和便携性使其成为 1 型和 2 型糖尿病患者的热门选择。此外，胰岛素帮浦提供持续的皮下胰岛素输注，模拟体内自然的胰岛素释放。这些设备可以精确控制胰岛素剂量，并可根据个人的独特需求进行程式设计。此外，与行动应用程式和连续血糖监测仪相结合的智慧胰岛素输送系统的开发进一步改善了糖尿病管理。这些设备能够即时追踪血糖水平并自动调整胰岛素，减轻患者持续监测和决策的负担。

日本胰岛素药物输送装置市场趋势：

日本的胰岛素药物输送装置市场有望大幅成长，这主要得益于几个引人注目的驱动因素。首先，糖尿病盛行率的上升是推动市场扩张的关键因素。此外，患者和医疗保健提供者对糖尿病管理的认识不断提高，以及及时注射胰岛素的重要性，也促进了市场的上升趋势。此外，胰岛素输送装置的技术进步，例如智慧胰岛素笔和穿戴式胰岛素帮浦的开发，正在提高患者的便利性和依从性。此外，老年人口的不断增长使得他们更容易患糖尿病，这也增加了对这些设备的需求。除此之外，日本不断上升的肥胖率和久坐不动的生活方式加剧了第 2 型糖尿病的发生率，进一步刺激了胰岛素药物输送设备市场的发展。此外，对个人化医疗和客製化胰岛素疗法的追求正在促进设备设计和功能的创新。此外，糖尿病管理产品的优惠报销政策预计将在预测期内推动日本市场的发展，这将激励患者采用先进的胰岛素药物输送装置。

日本胰岛素药物输送装置市场区隔：

类型洞察：

  • 药物
    • 基础胰岛素或长效胰岛素
  • 来得时（甘精胰岛素）
  • Levemir（地特胰岛素）
  • Toujeo（甘精胰岛素）
  • Tresiba（德谷胰岛素）
  • Basaglar（甘精胰岛素）
    • 推注胰岛素或速效胰岛素
  • NovoRapid/Novolog（门冬胰岛素）
  • Humalog（赖脯胰岛素）
  • Apidra（胰岛素谷赖氨酸）
  • FIASP（门冬胰岛素）
  • Admelog（赛诺菲赖脯胰岛素）
    • 传统人类胰岛素
  • 诺和灵/Mixtard/Actrapid/Insulatard
  • 优泌林
  • 因苏曼
    • 组合胰岛素
  • NovoMix（双相门冬胰岛素）
  • Ryzodeg（德谷胰岛素和门冬胰岛素）
  • Xultophy（德谷胰岛素和利拉鲁肽）
  • Soliqua/Suliqua（甘精胰岛素和利西拉来）
    • 生物相似药胰岛素
  • 甘精胰岛素生物相似药
  • 人类胰岛素生物相似药
  • 装置
    • 胰岛素帮浦
  • 胰岛素帮浦装置
  • 胰岛素帮浦储液器
  • 胰岛素输注器
    • 胰岛素笔
  • 可重复使用笔中的墨盒
  • 一次性胰岛素笔
    • 胰岛素注射器
    • 胰岛素喷射器

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本胰岛素药物输送装置市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本胰岛素药物输送装置市场有何影响？
  • 日本胰岛素药物输送装置市场依类型分为哪些类型？
  • 日本胰岛素药物输送装置市场的价值链分为哪些阶段？
  • 日本胰岛素药物输送装置的主要驱动因素和挑战是什么？
  • 日本胰岛素药物输送装置市场的结构是怎么样的？主要参与者是谁？
  • 日本胰岛素药物输送装置市场的竞争程度如何？

本报告回答的关键问题：

  • 日本胰岛素药物输送装置市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本胰岛素药物输送装置市场有何影响？
  • 日本胰岛素药物输送装置市场依类型分为哪些类型？
  • 日本胰岛素药物输送装置市场的价值链分为哪些阶段？
  • 日本胰岛素药物输送装置的主要驱动因素和挑战是什么？
  • 日本胰岛素药物输送装置市场的结构是怎么样的？主要参与者是谁？
  • 日本胰岛素药物输送装置市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本胰岛素药物输送装置市场 - 简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本胰岛素药物输送装置市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本胰岛素药物输送装置市场-分类：依类型

  • 药物
    • 概述
    • 市场区隔
      • 基础胰岛素或长效胰岛素
        • 来得时（甘精胰岛素）
        • Levemir（地特胰岛素）
        • Toujeo（甘精胰岛素）
        • Tresiba（德谷胰岛素）
        • Basaglar（甘精胰岛素）
      • 推注胰岛素或速效胰岛素
        • NovoRapid/Novolog（门冬胰岛素）
        • Humalog（赖脯胰岛素）
        • Apidra（胰岛素谷赖氨酸）
        • FIASP（门冬胰岛素）
        • Admelog（赛诺菲赖脯胰岛素）
      • 传统人类胰岛素
        • 诺和灵/Mixtard/Actrapid/Insulatard
        • 优泌林
        • 因苏曼
      • 组合胰岛素
        • NovoMix（双相门冬胰岛素）
        • Ryzodeg（德谷胰岛素和门冬胰岛素）
        • Xultophy（德谷胰岛素和利拉鲁肽）
        • Soliqua/Suliqua（甘精胰岛素和利西拉肽）
      • 生物相似药胰岛素
        • 甘精胰岛素生物相似药
        • 人类胰岛素生物相似药
  • 装置
    • 概述
    • 市场区隔
      • 胰岛素帮浦
        • 胰岛素帮浦装置
        • 胰岛素帮浦储液器
        • 胰岛素输注器
      • 胰岛素笔
        • 可重复使用笔中的墨盒
        • 一次性胰岛素笔
      • 胰岛素注射器
      • 胰岛素喷射器

第七章：日本胰岛素药物输送装置市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第八章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第九章：日本胰岛素药物输送装置市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 10 章：附录

简介目录
Product Code: SR112025A15120

Japan insulin drugs delivery devices market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.75% during 2025-2033. The increasing incidences of diabetes in Japan coupled with the development of new insulin formulations and drugs that require specialized delivery devices are primarily driving the market.

Insulin drugs delivery devices are essential tools for individuals suffering from diabetes, a chronic condition characterized by impaired insulin production or utilization. These devices enable precise and convenient administration of insulin, a hormone crucial for regulating blood sugar levels. One of the most notable advancements in insulin delivery is the insulin pen, which resembles a regular pen and allows for accurate dosing with a simple push of a button. Its discreet design and portability have made it a popular choice for type 1 and type 2 diabetics. Additionally, insulin pumps offer continuous subcutaneous insulin infusion, mimicking the natural insulin release in the body. These devices provide precise control over insulin dosage and can be programmed to match an individual's unique needs. Furthermore, the development of smart insulin delivery systems, which integrate with mobile apps and continuous glucose monitors, has further improved diabetes management. These devices enable real-time tracking of blood sugar levels and automated insulin adjustments, reducing the burden of constant monitoring and decision-making for patients.

Japan Insulin Drugs Delivery Devices Market Trends:

The insulin drugs delivery devices market in Japan is poised for significant growth, primarily due to several compelling drivers. Firstly, the rising prevalence of diabetes is a pivotal factor propelling market expansion. Moreover, the increasing awareness about diabetes management and the importance of timely insulin administration among patients and healthcare providers is contributing to the market's upward trajectory. Additionally, technological advancements in insulin delivery devices, such as the development of smart insulin pens and wearable insulin pumps, are driving patient convenience and adherence. Furthermore, the growing geriatric population, who are more susceptible to diabetes, is augmenting the demand for these devices. Apart from this, the escalating obesity rates and sedentary lifestyles in Japan are fueling the incidence of type 2 diabetes, further bolstering the insulin drugs delivery devices market. Additionally, the pursuit of personalized medicine and tailored insulin therapies is fostering innovation in device design and functionality. Moreover, favorable reimbursement policies for diabetes management products, which incentivize patients to adopt advanced insulin drugs delivery devices, are expected to drive the market in Japan during the forecast period.

Japan Insulin Drugs Delivery Devices Market Segmentation:

Type Insights:

  • Drug
    • Basal or Long-Acting Insulins
  • Lantus (Insulin Glargine)
  • Levemir (Insulin Detemir)
  • Toujeo (Insulin Glargine)
  • Tresiba (Insulin Degludec)
  • Basaglar (Insulin Glargine)
    • Bolus or Fast-Acting Insulins
  • NovoRapid/Novolog (Insulin aspart)
  • Humalog (Insulin lispro)
  • Apidra (Insulin glulisine)
  • FIASP (Insulin aspart)
  • Admelog (Insulin lispro Sanofi)
    • Traditional Human Insulins
  • Novolin/Mixtard/Actrapid/Insulatard
  • Humulin
  • Insuman
    • Combination Insulins
  • NovoMix (Biphasic Insulin aspart)
  • Ryzodeg (Insulin degludec and Insulin aspart)
  • Xultophy (Insulin degludec and Liraglutide)
  • Soliqua/Suliqua (Insulin glargine and Lixisenatide)
    • Biosimilar Insulins
  • Insulin Glargine Biosimilars
  • Human Insulin Biosimilars
  • Device
    • Insulin Pumps
  • Insulin Pump Devices
  • Insulin Pump Reservoirs
  • Insulin Infusion sets
    • Insulin Pens
  • Cartridges in reusable pens
  • Disposable insulin pens
    • Insulin Syringes
    • Insulin Jet Injectors

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan insulin drugs delivery devices market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan insulin drugs delivery devices market?
  • What is the breakup of the Japan insulin drugs delivery devices market on the basis of type?
  • What are the various stages in the value chain of the Japan insulin drugs delivery devices market?
  • What are the key driving factors and challenges in the Japan insulin drugs delivery devices?
  • What is the structure of the Japan insulin drugs delivery devices market and who are the key players?
  • What is the degree of competition in the Japan insulin drugs delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Insulin Drugs Delivery Devices Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Insulin Drugs Delivery Devices Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Insulin Drugs Delivery Devices Market - Breakup by Type

  • 6.1 Drug
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Basal or Long-Acting Insulins
        • 6.1.3.1.1 Lantus (Insulin Glargine)
        • 6.1.3.1.2 Levemir (Insulin Detemir)
        • 6.1.3.1.3 Toujeo (Insulin Glargine)
        • 6.1.3.1.4 Tresiba (Insulin Degludec)
        • 6.1.3.1.5 Basaglar (Insulin Glargine)
      • 6.1.3.2 Bolus or Fast-Acting Insulins
        • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
        • 6.1.3.2.2 Humalog (Insulin lispro)
        • 6.1.3.2.3 Apidra (Insulin Glulisine)
        • 6.1.3.2.4 FIASP (Insulin Aspart)
        • 6.1.3.2.5 Admelog (Insulin lispro Sanofi)
      • 6.1.3.3 Traditional Human Insulins
        • 6.1.3.3.1 Novolin/Mixtard/Actrapid/Insulatard
        • 6.1.3.3.2 Humulin
        • 6.1.3.3.3 Insuman
      • 6.1.3.4 Combination Insulins
        • 6.1.3.4.1 NovoMix (Biphasic Insulin aspart)
        • 6.1.3.4.2 Ryzodeg (Insulin Degludec and Insulin aspart)
        • 6.1.3.4.3 Xultophy (Insulin Degludec and Liraglutide)
        • 6.1.3.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
      • 6.1.3.5 Biosimilar Insulins
        • 6.1.3.5.1 Insulin Glargine Biosimilars
        • 6.1.3.5.2 Human Insulin Biosimilars
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Device
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 Insulin Pumps
        • 6.2.3.1.1 Insulin Pump Devices
        • 6.2.3.1.2 Insulin Pump Reservoirs
        • 6.2.3.1.3 Insulin Infusion Sets
      • 6.2.3.2 Insulin Pens
        • 6.2.3.2.1 Cartridges in Reusable Pens
        • 6.2.3.2.2 Disposable Insulin Pens
      • 6.2.3.3 Insulin Syringes
      • 6.2.3.4 Insulin Jet Injectors
    • 6.2.4 Market Forecast (2025-2033)

7 Japan Insulin Drugs Delivery Devices Market - Competitive Landscape

  • 7.1 Overview
  • 7.2 Market Structure
  • 7.3 Market Player Positioning
  • 7.4 Top Winning Strategies
  • 7.5 Competitive Dashboard
  • 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

  • 8.1 Company A
    • 8.1.1 Business Overview
    • 8.1.2 Product Portfolio
    • 8.1.3 Business Strategies
    • 8.1.4 SWOT Analysis
    • 8.1.5 Major News and Events
  • 8.2 Company B
    • 8.2.1 Business Overview
    • 8.2.2 Product Portfolio
    • 8.2.3 Business Strategies
    • 8.2.4 SWOT Analysis
    • 8.2.5 Major News and Events
  • 8.3 Company C
    • 8.3.1 Business Overview
    • 8.3.2 Product Portfolio
    • 8.3.3 Business Strategies
    • 8.3.4 SWOT Analysis
    • 8.3.5 Major News and Events
  • 8.4 Company D
    • 8.4.1 Business Overview
    • 8.4.2 Product Portfolio
    • 8.4.3 Business Strategies
    • 8.4.4 SWOT Analysis
    • 8.4.5 Major News and Events
  • 8.5 Company E
    • 8.5.1 Business Overview
    • 8.5.2 Product Portfolio
    • 8.5.3 Business Strategies
    • 8.5.4 SWOT Analysis
    • 8.5.5 Major News and Events

9 Japan Insulin Drugs Delivery Devices Market - Industry Analysis

  • 9.1 Drivers, Restraints and Opportunities
    • 9.1.1 Overview
    • 9.1.2 Drivers
    • 9.1.3 Restraints
    • 9.1.4 Opportunities
  • 9.2 Porters Five Forces Analysis
    • 9.2.1 Overview
    • 9.2.2 Bargaining Power of Buyers
    • 9.2.3 Bargaining Power of Suppliers
    • 9.2.4 Degree of Competition
    • 9.2.5 Threat of New Entrants
    • 9.2.6 Threat of Substitutes
  • 9.3 Value Chain Analysis

10 Appendix